These results should help mollify the disappointment of the deferred sales that were the subject of the January trading update. Underlying sales growth of 17%, evidence of firm cost control through the delivery of a profit (adjusted PBT of £0.1m), further growth in the order book (up £0.3m to £17.4m since January), and the fact that the deferred opportunities remain in the pipeline all offer reassurance of a decent foundation for future growth. We make no changes to our revenue and profit expect ....
